BACKGROUND: Stereotactic radiosurgery (SRS) offers excellent local control for brain metastases (BM) with low rates of toxicity. Radiation necrosis (RN) may occur after treatment and is challenging to distinguish from local recurrence (LR). We evaluated enlarging brain lesions following SRS that were subsequently biopsied to differentiate RN versus LR. METHODS: This study reviewed patients receiving SRS for BM between 2008 and 2012 who underwent a biopsy for suspicion of RN versus LR on MRI. Data collection included demographics, radiation parameters, imaging findings, and post-biopsy pathology. Kaplan-Meier methods determined overall survival. Fisher's exact test assessed for association between lesion biopsy result and variables of interest. RESULTS: Thirty-four patients with 35 biopsied BM were included. Lesions were biopsied a median of 8.8 months after SRS. Most patients had primary lung cancer (11; 31.4%). Eleven (31.4%) biopsies were positive for LR and 24 (68.6%) showed RN only. Median overall survival was longer for patients with RN (31.0 mo) than for patients with LR (14.5 mo; P = 0.135). Time from SRS to biopsy was significantly different between RN and LR groups; 10 lesions (52.5%) biopsied ≤9 months after SRS showed LR, whereas 1 lesion (6.3%) biopsied >9 months after SRS showed LR (P = 0.004). For 16 (65.7%) lesions, management was changed or directed by the biopsy results. CONCLUSIONS: Stereotactic biopsy for accessible enlarging lesions after SRS appears diagnostically valuable in patients with few lesions and changes clinical management. RN should be suspected in patients with an enlarging lesion more than 9 months post-SRS.
BACKGROUND: Stereotactic radiosurgery (SRS) offers excellent local control for brain metastases (BM) with low rates of toxicity. Radiation necrosis (RN) may occur after treatment and is challenging to distinguish from local recurrence (LR). We evaluated enlarging brain lesions following SRS that were subsequently biopsied to differentiate RN versus LR. METHODS: This study reviewed patients receiving SRS for BM between 2008 and 2012 who underwent a biopsy for suspicion of RN versus LR on MRI. Data collection included demographics, radiation parameters, imaging findings, and post-biopsy pathology. Kaplan-Meier methods determined overall survival. Fisher's exact test assessed for association between lesion biopsy result and variables of interest. RESULTS: Thirty-four patients with 35 biopsied BM were included. Lesions were biopsied a median of 8.8 months after SRS. Most patients had primary lung cancer (11; 31.4%). Eleven (31.4%) biopsies were positive for LR and 24 (68.6%) showed RN only. Median overall survival was longer for patients with RN (31.0 mo) than for patients with LR (14.5 mo; P = 0.135). Time from SRS to biopsy was significantly different between RN and LR groups; 10 lesions (52.5%) biopsied ≤9 months after SRS showed LR, whereas 1 lesion (6.3%) biopsied >9 months after SRS showed LR (P = 0.004). For 16 (65.7%) lesions, management was changed or directed by the biopsy results. CONCLUSIONS: Stereotactic biopsy for accessible enlarging lesions after SRS appears diagnostically valuable in patients with few lesions and changes clinical management. RN should be suspected in patients with an enlarging lesion more than 9 months post-SRS.
Authors: Jacob A Miller; Elizabeth E Bennett; Roy Xiao; Rupesh Kotecha; Samuel T Chao; Michael A Vogelbaum; Gene H Barnett; Lilyana Angelov; Erin S Murphy; Jennifer S Yu; Manmeet S Ahluwalia; John H Suh; Alireza M Mohammadi Journal: Int J Radiat Oncol Biol Phys Date: 2016-09-01 Impact factor: 7.038
Authors: Nancy U Lin; Eudocia Q Lee; Hidefumi Aoyama; Igor J Barani; Daniel P Barboriak; Brigitta G Baumert; Martin Bendszus; Paul D Brown; D Ross Camidge; Susan M Chang; Janet Dancey; Elisabeth G E de Vries; Laurie E Gaspar; Gordon J Harris; F Stephen Hodi; Steven N Kalkanis; Mark E Linskey; David R Macdonald; Kim Margolin; Minesh P Mehta; David Schiff; Riccardo Soffietti; John H Suh; Martin J van den Bent; Michael A Vogelbaum; Patrick Y Wen Journal: Lancet Oncol Date: 2015-05-27 Impact factor: 41.316
Authors: E Shaw; C Scott; L Souhami; R Dinapoli; R Kline; J Loeffler; N Farnan Journal: Int J Radiat Oncol Biol Phys Date: 2000-05-01 Impact factor: 7.038
Authors: G Minniti; M Salvati; R Muni; G Lanzetta; M F Osti; E Clarke; A Costa; A Bozzao; G Trasimeni; R Maurizi Enrici Journal: Anticancer Res Date: 2010-07 Impact factor: 2.480
Authors: John P Kirkpatrick; Zhiheng Wang; John H Sampson; Frances McSherry; James E Herndon; Karen J Allen; Eileen Duffy; Jenny K Hoang; Zheng Chang; David S Yoo; Chris R Kelsey; Fang-Fang Yin Journal: Int J Radiat Oncol Biol Phys Date: 2014-10-21 Impact factor: 7.038
Authors: Timothy Korytko; Tomas Radivoyevitch; Valdir Colussi; Barry W Wessels; Kunjan Pillai; Robert J Maciunas; Douglas B Einstein Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-14 Impact factor: 7.038
Authors: Paul D Brown; Kurt Jaeckle; Karla V Ballman; Elana Farace; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Fred G Barker; Richard Deming; Stuart H Burri; Cynthia Ménard; Caroline Chung; Volker W Stieber; Bruce E Pollock; Evanthia Galanis; Jan C Buckner; Anthony L Asher Journal: JAMA Date: 2016-07-26 Impact factor: 56.272
Authors: David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran Journal: Lancet Date: 2004-05-22 Impact factor: 79.321
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Timothy J Kaufmann; Marion Smits; Jerrold Boxerman; Raymond Huang; Daniel P Barboriak; Michael Weller; Caroline Chung; Christina Tsien; Paul D Brown; Lalitha Shankar; Evanthia Galanis; Elizabeth Gerstner; Martin J van den Bent; Terry C Burns; Ian F Parney; Gavin Dunn; Priscilla K Brastianos; Nancy U Lin; Patrick Y Wen; Benjamin M Ellingson Journal: Neuro Oncol Date: 2020-06-09 Impact factor: 12.300
Authors: Tejus A Bale; Soo-Ryum Yang; James P Solomon; Khedoudja Nafa; Sumit Middha; Jacklyn Casanova; Justyna Sadowska; Anna Skakodub; Hamza Ahmad; Helena A Yu; Greg J Riely; Mark G Kris; Sarat Chandarlapaty; Marc K Rosenblum; Igor Gavrilovic; Matthias A Karajannis; Elena Pentsova; Alexandra Miller; Adrienne Boire; Ingo Mellinghoff; Michael F Berger; Ahmet Zehir; Marc Ladanyi; Ryma Benayed; Maria E Arcila Journal: J Mol Diagn Date: 2021-03-27 Impact factor: 5.341
Authors: Gokoulakrichenane Loganadane; Frédéric Dhermain; Guillaume Louvel; Paul Kauv; Eric Deutsch; Cécile Le Péchoux; Antonin Levy Journal: Front Oncol Date: 2018-09-05 Impact factor: 6.244
Authors: Eric W Sankey; Vadim Tsvankin; Matthew M Grabowski; Gautam Nayar; Kristen A Batich; Aida Risman; Cosette D Champion; April K S Salama; C Rory Goodwin; Peter E Fecci Journal: Cancer Med Date: 2019-09-30 Impact factor: 4.452
Authors: Albert H Kim; Steven Tatter; Ganesh Rao; Sujit Prabhu; Clark Chen; Peter Fecci; Veronica Chiang; Kris Smith; Brian J Williams; Alireza M Mohammadi; Kevin Judy; Andrew Sloan; Zulma Tovar-Spinoza; James Baumgartner; Constantinos Hadjipanayis; Eric C Leuthardt Journal: Neurosurgery Date: 2020-09-01 Impact factor: 4.654